HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Steers Bimatoprost Eyelash Enhancer To Drug, Not Cosmetic, Market

This article was originally published in The Rose Sheet

Executive Summary

Allergan says it will file a new drug application with FDA later this year for the eyelash growth stimulant bimatoprost, the key ingredient in cosmetic offerings that caught the drug company's - and FDA's - watchful eye earlier this year

You may also be interested in...



Allergan Adds To Growth Areas With Acquisition Of Eye-Disease Compounds

Deal with UK’s Asterand nets preclinical prostaglandin receptor agonists with potential in glaucoma, other eye conditions.

Jan Marini Ceases Eyelash Product Sales Due To Allergan Suit, FDA Threat

Jan Marini Skin Research (JMSR) is suspending sales of its two Age Intervention eyelash products in the U.S. - citing an uncertain regulatory environment and the daunting prospect of litigation - and focusing on its core skin-care line and opportunities abroad

Jan Marini Focused On Damage Control Following FDA Seizure Of Eyelash Item

Jan Marini issued a statement Nov. 16 stressing that its Age Intervention Eyelash product has not been manufactured or distributed since September of last year, in response to a release from FDA announcing seizure of the "potentially harmful" product

Related Content

UsernamePublicRestriction

Register

RS015466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel